ESTRO 2022 - Abstract Book

S1024

Abstract book

ESTRO 2022

Results The mean age at diagnosis was 53 (33-77) years. Thirteen (26%) patients had inflammatory BC and 37 had stage T4b BC. All patients underwent chemotherapy which was neo-adjuvant in 76% of cases. Mastectomy was performed for 96% of patients, whereas two patients had conservative surgery. Regional lymph nodes irradiation was performed for 47 (94%) of patients. Additional boost to the thoracic wall/tumor bed was delivered in 40% of cases. Eighty percent of patients experienced acute skin toxicity with 66% of grade 1 radiation dermatitis and 14% of grade 2 radiation dermatitis. No grade 3-4 radiation dermatitis was reported. Sixteen patients reported dysphagia which was well managed with non-steroidal anti-inflammatory drugs. The median follow-up was 20 (2-40) months. Late skin toxicity was observed in 48% of patients with 36% of skin colour change and 12% of radiation induced fibrosis. Twenty-six (52%) did not report any late cutaneous toxicity. Local recurrence was observed in 4 women. The mean time to local failure was 13 months. Nine patients (18%) had distant metastatic failure. Disease free survival at 36 months was 87.8% whereas metastasis free survival was 82.8%. Conclusion Early outcomes of hypofractionated radiotherapy for stage T4 breast cancer seemed comparable to conventional breast cancer radiotherapy. Considering the important socio-economic impact, this may encourage its use in low middle income countries. Nonetheless, safety and efficacy of hypofractionated radiotherapy in locally advanced breast cancer need to be further studied in larger cohort.

PO-1206 PATIENTS NEEDS UNDERGOING BREAST RADIOTHERAPY FOR THE DEVELOPMENT OF A MOBILE APPLICATION (RADIOSA) P. Matteucci 1 , E. Ippolito 1 , S. Silipigni 1 , C. Talocco 1 , G.M. Petrianni 1 , V. Palumbo 1 , E. Onorati 1 , C. Greco 1 , V. Cirnigliaro 1 , M. Fiore 1 , S. Ramella 1

1 Campus Biomedico, Radiotherapy, Rome, Italy

Purpose or Objective Breast cancer requires integrated multimodal treatments, including surgery, chemotherapy, and radiation therapy. Monitoring of symptoms during treatment can help to identify those patients who needs medical interventions. Use of mobile Apps in the radiotherapy-oncology field gives the possibility of daily monitoring and supportive care for patients undergoing breast radiotherapy. A few mobile Apps are specific to breast cancer and to best of our knowledge no App is specific for patients treated with radiotherapy. The aim of this survey is to test the acceptability and satisfaction related to the development of a dedicated mobile application (RADIOSA project: Mobile Application on Breast Radiotherapy) among breast cancer patients undergoing radiotherapy. Materials and Methods Qualitative questionnaires were administered from May 17, 2021 to June 4, 2021 on a sample of female patients undergoing breast adjuvant radiotherapy treatment to understand which aspects could be most useful for them to be included in the new mobile App. Results 30 patients completed the questionnaires (median age 64 years; range 41-88 years). All patients (100%) welcomed the proposal for dedicated mobile App. Of these, 90% of patients preferred the possibility of requesting an emergency visit, to view tutorials on the management of local side effects such as skin toxicity, to perform physiotherapy exercises to facilitate correct positioning of the arm during radiotherapy. 87% of patients were in favor of FAQ area and the possibility of breast massage tutorials, while 80% of patients appreciated the option of following a calendar with planning of all radiotherapy sessions. Instead, 67% of patients showed no interest in receiving notifications regarding the timing of cream application, while 57% patients showed little interest in viewing tutorials on how to hold their breath for those radiotherapy sessions involving the technique of voluntary inspiration (however among these patients, only 14% of patients was receiving breast hold radiotherapy). Finally, only 7% patients provided their suggestion in the free section of survey, asking to insert a dedicated section for psychological support. Conclusion "RADIOSA" project was welcomed by all patients. After this preliminary phase, we have decided to add a section for the request of psychological support in the mobile App. We are now proceeding to develop the application with the goal of creating the simplest and most intuitive interface as possible.

PO-1207 Partial breast irradiation with IORT using Xoft®. Experience at Catalan Institute of Oncology

S. Comas Antón 1 , S. Moreno 1 , G. Molina 1 , R. Ballester 2 , E. Montes 3 , M.A. Luna 4 , M.I. Pascual 5 , M. Villalobos 6 , G. Meca 1 , S. Villà 1 1 Catalan Institute of Oncology. ICO Badalona, Radiation Oncology, Badalona (Barcelona), Spain; 2 Catalan Institute of Oncology. ICO Badalona, Radiation Oncology, Badalona (Barcelona), Spain; 3 Catalan Institute of Oncology. ICO Badalona, Radiation Oncology. Medical Physics, Radiation Oncology, Spain; 4 Hospital Universitari Germans Trias i Pujol, Gynecology, Badalona (Barcelona), Spain; 5 Hospital Universitari Germans Trias i Pujol, General Surgery, Badalona (Barcelona), Spain; 6 Catalan Institute of Oncology. ICO Badalona, , Radiation Oncology, Badalona (Barcelona), Spain

Purpose or Objective